STOCK TITAN
  1. Home
  2. Sec-filings
  3. BDRX
  4. [EFFECT] Biodexa Pharmaceuticals Plc SEC Filing

[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 21, 2025
Accession Number: 0001214659-25-016809
Submission Type: POS AM
CIK: 0001643918
Company Name: Biodexa Pharmaceuticals Plc
File Number: 333-272693

Source: View Original Filing on SEC EDGAR

Stock BDRX logo
Biodexa Pharmaceuticals plc

NASDAQ:BDRX

BDRX Rankings

#6851 Ranked by Market Cap
N/A Ranked by Dividends

BDRX Latest News

Jan 5, 2026
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
Dec 18, 2025
Biodexa Announces Pricing of $10 Million Public Offering
Dec 1, 2025
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Nov 24, 2025
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Nov 3, 2025
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

BDRX Latest SEC Filings

Dec 18, 2025
[424B4] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(4)
Dec 18, 2025
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3)
Dec 18, 2025
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing
Dec 18, 2025
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3)
Dec 18, 2025
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3)

BDRX Stock Data

1.92M
613.62k
0.95%
6.25%
0.69%
Biotechnology
Healthcare
Link
United Kingdom
Cardiff